1. 厚朴酚、和厚朴酚对脂多糖诱导 小鼠肠道损伤的抗炎作用及机制研究.
- Author
-
李平萍, 师盼盼, 李柱, 周俊娟, and 黄鹏
- Abstract
The purpose of this study was to study the anti-inflammatory effects of magnolol and honokiol on intestinal injury induced by lipopolysaccharide in mice. A total of 135 healthy male ICR mice weighing 18~22 g were randomly divided into nine groups with three replicates in each group and five mice in each replicate. The groups were control group, model group, positive drug group (100 mg/kg berberine hydrochloride) and low, medium and high dose groups of magnolol and honokiol (25, 50, 100 mg/kg). Before modeling, mice were given gastric perfusion for seven days according to the test group, while the control group and model group were given gavage of normal saline. Inflammation was induced by intraperitoneal injection of 6 mg/kg lipopolysaccharide in mice except the control group on the 7th day. The results showed that magnolol and honokiol could reduce the diarrhea index and the level of pro-inflammatory cytokine interleukin-6, relieve the symptoms of enteritis, improve the intestinal morphology and restore the balance of intestinal microflora. Protein kinase B (AKT), inhibitor of apoptosis in B cell lymphoma (BCL-XL) and interleukin-18 receptor 1 (IL-18R1) were potential therapeutic targets for inflammation. Magnolol played an anti-inflammatory role by upregulating AKT, BCL-XL and the activating phosphatidylinositol 3 kinase-protein kinase (BPI3K-Akt) signaling pathway. On the contrary, the anti-inflammatory mechanism of honokiol involves down-regulating inflammation-related genes, including IL-18R1 and cyclic adenosine monophosphate effector element binding protein (CREB), thus inhibiting the tumor necrosis factor (TNF) signaling pathway. The study indicates that the appropriate dosage of magnolol, honokiol and honokiol is 100 mg/kg for relieving and treating intestinal injury. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF